BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back
This article was originally published in The Pink Sheet Daily
With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.
You may also be interested in...
Making The Grade? Big Pharma Deals With Academia Begin To Score
With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.
Is Global Deal-Making On The Decline?
A recent report from the consulting firm Campbell Alliance asked just that question and then brought the results to a group of high-level biopharma deal makers to get their take at the annual BIO convention in San Diego.
Business Goes On For AstraZeneca, Even After Pfizer
AstraZeneca’s business development executives sit down with “The Pink Sheet” and talk about their process, almost being acquired, and partnering at the BIO convention in 2014.